These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 3115077)

  • 1. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
    Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
    Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
    Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
    Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR; Lijnen HR; Stassen JM; Collen D
    Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
    Kirshenbaum JM; Bahr RD; Flaherty JT; Gurewich V; Levine HJ; Loscalzo J; Schumacher RR; Topol EJ; Wahr DW; Braunwald E
    Am J Cardiol; 1991 Dec; 68(17):1564-9. PubMed ID: 1746455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
    Van de Werf F; Vanhaecke J; de Geest H; Verstraete M; Collen D
    Circulation; 1986 Nov; 74(5):1066-70. PubMed ID: 2429783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F; Jang IK; Collen D
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.
    Lancet; 1989 Apr; 1(8643):863-8. PubMed ID: 2564949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
    Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
    Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
    J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local intra-arterial fibrinolysis in acute hemispheric stroke: effect of occlusion type and fibrinolytic agent on recanalization success and neurological outcome.
    Eckert B; Kucinski T; Neumaier-Probst E; Fiehler J; Röther J; Zeumer H
    Cerebrovasc Dis; 2003; 15(4):258-63. PubMed ID: 12686789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clot-selective coronary thrombolysis with pro-urokinase.
    Loscalzo J; Wharton TP; Kirshenbaum JM; Levine HJ; Flaherty JT; Topol EJ; Ramaswamy K; Kosowsky BD; Salem DN; Ganz P
    Circulation; 1989 Apr; 79(4):776-82. PubMed ID: 2494004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
    Spriggs DJ; Stassen JM; Hashimoto Y; Collen D
    Blood; 1989 Apr; 73(5):1207-12. PubMed ID: 2495034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.